Day: September 8, 2021

LOS ANGELES, Sept. 08, 2021 (GLOBE NEWSWIRE) — via InvestorWire — FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers FuelPositive’s recent announcement that it has hired engineer Dr. Ghassan Chehade, one of the co-inventors named on the provisional patent of the company’s technology that will produce carbon-free ammonia (NH3), as Lead Project Engineer. To hear the audio production, visit: https://nnw.fm/frM0k To read the original...

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15. Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company, which will be available on-demand beginning September 13 at 7:00 am EDT and will be archived for 90 days. A link to the webcast will be available at https://investors.werewolftx.com/news-and-events/events. About Werewolf Therapeutics, Inc. Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the...

Josh WilhelmDirector of Islet Manufacturing and R&D at the Schulze Diabetes Institute (“SDI”)MINNEAPOLIS, MN, US, Sept. 08, 2021 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV) (the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Josh Wilhelm has accepted a position with the Company as its new Director of Manufacturing. “We are incredibly fortunate to have secured a manufacturing professional such as Josh who possesses expertise in cGMP manufacturing, process engineering, and quality systems,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Josh is an experienced professional in assembling, coordinating and training manufacturing teams, and has already brought...

Figure 1Freegold Mountain Project location Map and area of 2021 drilling program.Photo 1N21-01 at 19m – Oxidized limonite after pyrite skarn replacement mineralization within YTT (Nucleus Deposit).Photo 2N21-02 at 114.20m – Epithermal-style quartz-pyrite-arsenopyrite veinlet within argillic altered YTT (Nucleus Deposit)Photo 3N21-05 at 174.14m – Semi-massive sulphide (marcasite +/- pyrite dominant) replacement within iron carbonate altered YTT (Big Creek South Fault area).Photo 4O21-01 at 159.8m – Epithermal style chalcopyrite-molybdenite-bornite veinlet cutting Microgranite and YTT (Orbit Zone).Photo 5RVD21-03 at 411.50m – Epithermal style scheelite and chalcopyrite WAu breccia mineralization within argillic altered Revenue granodiorite.Photo...

BEYOND / HELLO™ Colwyn Continues to Expand Access and Will Begin Serving Medical Marijuana Patients in the Philadelphia Region on Wednesday, September 8th at 10:00 a.m.Jushi Holdings Inc. Opens 22nd BEYOND / HELLO™ Retail Location Nationwide and 15th Store in PennsylvaniaJushi Holdings Inc. (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced the opening of its 22nd BEYOND / HELLO™ retail location nationwide, 15th medical marijuana dispensary in Pennsylvania and 7th storefront in the Greater Delaware Valley: BEYOND / HELLO™ Colwyn. Commenting on the opening Jim Cacioppo, Chief Executive Officer, Chairman and Founder of Jushi, said, “Our subsidiaries’ fifteenth location in Pennsylvania and seventh location in the Greater Delaware Valley Region demonstrates our commitment to expand...

Name change reflects investment in, and emphasis on, data-driven, patient-centric care relating to the company’s innovative PRP-PBMC treatment for chronic lung disorders. CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) — H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders, today announced the launch of its newly-named ‘Centers for Respiratory Health’. Effective immediately, the Company’s “Lung Health Institute” facilities will begin operating under the new name. The change is evolutionary and represents a commitment to data-driven, real-world evidence, along with the need to more accurately capture the broadening scope of the work the H-CYTE clinical development team and its medical professionals accomplish...

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13 – 15, 2021. Ms. Johnson’s presentation will be available on-demand for conference participants beginning at 7:00 a.m. Eastern Time on Wednesday, September 13th. Registration and other information about the event can be found at https://hcwevents.com/annualconference/. Following the conclusion of the conference, an archived webcast of Ms. Johnson’s presentation will be available until September 29, 2021 under “Presentations, Events & Webcasts” in the Investors section of the company’s...

Company Commences Second Study of Trypsin Activated Abuse Protected (TAAP) Opioid, PF614, on September 7, 2021 SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced that it has enrolled the first cohort of subjects in a clinical study PF614-102 entitled “A Phase 1b, Randomized, 2-Part Single-Center Study to Evaluate the Pharmacokinetics and Safety of Multiple-Ascending Oral Doses of PF614 and the Food Effect and Bioavailability/Bioequivalence of Single Oral Doses of PF614 Relative to OxyContin in Healthy Adult Subjects.” The study is being conducted by Matthew Johnston, MD, PRA Health Sciences,...

FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has submitted two new drug applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and vonoprazan in combination with amoxicillin (vonoprazan dual therapy) as a treatment for Helicobacter pylori (H. pylori) infection in adults. With current standard of care therapies, H. pylori eradication rates have declined in the U.S. If approved, vonoprazan-based treatments offer two new therapeutic options that have demonstrated superior eradication rates as compared to...

Conference to Take Place Virtually, September 13-15, 2021 CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The prerecorded presentation will be available starting at 7 a.m. ET on September 13, 2021 and will be accessible via the conference’s virtual platform by registered conference attendees. The presentation will be archived and available for viewing for 90 days, following the conference. Dr. Cobuzzi will provide...